<SEC-DOCUMENT>0001171843-12-000304.txt : 20120131
<SEC-HEADER>0001171843-12-000304.hdr.sgml : 20120131
<ACCEPTANCE-DATETIME>20120131164517
ACCESSION NUMBER:		0001171843-12-000304
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20120131
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120131
DATE AS OF CHANGE:		20120131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ULTRALIFE CORP
		CENTRAL INDEX KEY:			0000875657
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690]
		IRS NUMBER:				161387013
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20852
		FILM NUMBER:		12559759

	BUSINESS ADDRESS:	
		STREET 1:		2000 TECHNOLOGY PARKWAY
		CITY:			NEWARK
		STATE:			NY
		ZIP:			14513
		BUSINESS PHONE:		3153327100

	MAIL ADDRESS:	
		STREET 1:		2000 TECHNOLOGY PARKWAY
		CITY:			NEWARK
		STATE:			NY
		ZIP:			14513

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ULTRALIFE BATTERIES INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>document.htm
<DESCRIPTION>FORM 8-K FILING DOCUMENT
<TEXT>
<html>

	<head>
		<title>Form 8-K Filing</title>
	</head>

	<body>
		<p align="center">UNITED STATES<br>
			SECURITIES AND EXCHANGE COMMISSION<br>
			Washington, D.C. 20549<br>
		</p>
		<p align="center">FORM 8-K</p>
		<p align="center"><font size="2">CURRENT REPORT<br>
				Pursuant to Section 13 OR 15(d) of<br>
					The Securities Exchange Act of 1934</font></p>
		<p align="center"><font size="2">Date of Report (Date of earliest event reported) <br>January 31, 2012</font></p>
		<p align="center"><font size="4"><u>Ultralife Corporation</u></font><br>
			<font size="2">(Exact name of registrant as specified in its charter)</font></p>
		<!-- Registrant's State of Inc, File and IRS Number -->
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td align="center" colspan="2"><font size="2"><u>Delaware</u></font></td>
			</tr>
			<tr valign="top">
				<td align="center" colspan="2"><font size="2">(State or other jurisdiction<br>

						of incorporation) </font></td>
			</tr>
			<tr valign="top">
				<td width="50%" align="center"></td>
				<td width="50%" align="center"></td>
			</tr>
			<tr valign="top">
				<td width="50%" align="center"><font size="2"><u>000-20852</u></font></td>
				<td width="50%" align="center"><font size="2"><u>16-1387013</u></font></td>
			</tr>
			<tr valign="top">
				<td width="50%" align="center"><font size="2">(Commission File Number) </font></td>
				<td width="50%" align="center"><font size="2">(IRS Employer<br>
						Identification No.) </font></td>
			</tr>
		</table>
		<!-- Registrant's Postal Addess and Zip Code --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="bottom">
				<td width="50%" align="center"><font size="2"><u>2000 Technology Parkway, Newark, New York</u></font></td>
				<td width="50%" align="center"><font size="2"><u>14513</u></font></td>
			</tr>
			<tr valign="top">
				<td width="50%" align="center"><font size="2">(Address of principal executive offices)</font></td>
				<td width="50%" align="center"><font size="2">(Zip Code)</font></td>
			</tr>
		</table>
		<p align="center"><font size="2"><u>(315) 332-7100</u><br>
			Registrant's telephone number, including area code</font></p>
		<!--<p align="center"><br>
			<font size="2"><u>________________________________________________________________________________</u><br>
			(Former name or former address, if changed since last report)</font></p>-->
		<!-- Simultaneous filing obligation checkboxes --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td colspan="3"><font size="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):<br>
						<br>
					</font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></td>
			</tr>
		</table>
		<br>
		<hr noshade="1">
		<font size="2"></font>
		<p><font size="2">Item 8.01. Other Events.</font></p>
		<p><font size="2"><p>
	Ultralife Corporation (NASDAQ: ULBI) has received a contract to supply 2,319 of its A-320 amplifier systems to a major international defense contractor. Due to the sensitive nature of this contract, the company is not able to disclose the total value of the contract. Deliveries will commence in the first half of 2012.</p>
<p>
	 </p>
<p>
	The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed to be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.</p>
</font></p>
		<font size="2"></font>
		<p><font size="2">Item 9.01. Financial Statements and Exhibits.</font></p>
		<p><font size="2"><table border="0" cellpadding="0" cellspacing="0">

		<tr>
			<td>
				<font size="2">(a)</font></td>
			<td rowspan="3" width="15">
				 </td>
			<td>
				<font size="2">Exhibits.</font></td>
		</tr>
		<tr>
			<td>
				 </td>
			<td>
				 </td>
		</tr>
		<tr>
			<td>
				 </td>
			<td>
				<font size="2">99.1 Press Release dated January 31, 2012</font></td>
		</tr>

</table>
</font></p>
		<hr noshade="1">
		<!-- Registrant's Signature -->
		<p align="center"><font size="2">SIGNATURE</font></p>
		<p><font size="2">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="47%"><font size="2">&nbsp;</font></td>
				<td colspan="2">Ultralife Corporation<br>
					<br>
					</td>
			</tr>
			<tr valign="top">
				<td width="47%">
					<p><font size="2">Date: January 31, 2012</font></p>
				</td>
				<td width="5%"><font size="2">&nbsp;By: &nbsp;&nbsp;</font></td>
				<td width="47%"><font size="2"><u>/s/ PETER F. COMERFORD</u><br>
					Peter F. Comerford<br>
					<i>Vice President of Administration<br>General Counsel and Secretary</i></font></td>
			</tr>
		</table>
		<font size="2"><hr />
<p>
	 </p>
<p align="center">
	<b>INDEX TO EXHIBITS</b></p>
<p>
	 </p>
<table border="0" cellpadding="0" cellspacing="0">

		<tr>
			<td>
				<font size="2">(99)</font></td>
			<td rowspan="3" width="15">
				 </td>
			<td>
				<font size="2">Additional Exhibits</font></td>
		</tr>
		<tr>
			<td>
				 </td>
			<td>
				 </td>
		</tr>
		<tr>
			<td>
				 </td>
			<td>
				<font size="2">99.1 Press Release dated January 31, 2012</font></td>
		</tr>

</table>
</font>
	</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>newsrelease.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>Ultralife Corporation Receives International Communications Systems Contract</title></head><body><p align="right">EXHIBIT 99.1</p><h3 align="center">Ultralife Corporation Receives International Communications Systems Contract</h3><p>NEWARK, N.Y., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Ultralife Corporation (Nasdaq:ULBI) has received a contract to supply 2,319 of its A-320 amplifier systems to a major international defense contractor. Due to the sensitive nature of this contract, the company is not able to disclose the total value of the contract. Deliveries will commence in the first half of 2012.</p><p>
	"This contract demonstrates progress towards the strategic expansion of our core U.S. government and defense business into a broader global presence with international allies," said Michael D. Popielec, Ultralife's president and chief executive officer. "As we continue to develop new products across our business, our amplifier platform provides a technically advanced building block for the increasingly complex, secure communications systems required for soldier modernization. In this case, our amplifiers have been selected as a critical component of the secure communications backbone for a multi-phased, strategic command, control, and communications modernization program."</p><p>
	<strong>About Ultralife Corporation</strong></p><p>
	Ultralife Corporation serves its markets with products and services ranging from portable power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.</p><p>
	Headquartered in Newark, New York, the company's business segments include: Battery &amp; Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorp.com.</p><p>
	This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: uncertain global economic conditions, increased competitive environment and pricing pressures, disruptions related to restructuring actions and delays. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.</p><pre>CONTACT: Ultralife Corporation
         Philip Fain
         (315) 332-7100
         pfain@ulbi.com

         Investor Relations Contact:
         Lippert/Heilshorn &amp; Associates
         Jody Burfening
         (212) 838-3777
         jburfening@lhai.com</pre></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
